An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

GasthuisZusters Antwerpen, Wilrijk

Parkville Cancer Clinical Trial Unit (PCCTU), Melbourne

Seoul National University Bundang Hospital, Seongnam-si

C.H. Regional Reina Sofia - PPDS, Córdoba

Istituto Clinico Humanitas, Rozzano

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

Istituto Europeo Di Oncologia, Milan

Clinica Universidad de Navarra-Madrid, Madrid

START Madrid-FJD, Hospital Fundacion Jimenez Diaz, Madrid

Clinica Universitaria de Navarra, Pamplona

SCRI Oncology Partners, Nashville

Hospital Clinico Universitario de Valencia, Valencia

City of Hope Comprehensive Cancer Center, Ann Arbor

The University of Oklahoma Health Sciences Center, Oklahoma City

Honor Health Research Institute, Scottsdale

Stanford Health Centre - Palo Alto, Palo Alto

University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco

Yale University, New Haven

Hospital de Clinicas de Porto Alegre HCPA PPDS, Porto Alegre

Instituto do Cancer do Estado de Sao Paulo - ICESP, São Paulo

Princess Margaret Hospital, Toronto

Sir Mortimer B Davis Jewish General Hospital, Montreal

Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis, Amsterdam

VU Medisch Centrum, Amsterdam

Universitair Medisch Centrum Groningen, Groningen

Seoul National University Hospital, Seoul

Severance Hospital Yonsei University Health System - PPDS, Seoul

Asan Medical Center - PPDS, Seoul

Samsung Medical Center - PPDS, Seoul